EMCURE

Financial Performance - Q2 FY27 Consolidated Revenue from Operations ₹2,820Cr vs ₹2,268Cr (▲24.3% YoY) - EBITDA ₹575Cr vs ₹439Cr (▲31% YoY) - Net Profit after tax (PAT) ₹325Cr vs ₹252Cr (▲29% YoY) - EBITDA Margin 20.4% vs 19.4% (▲100bps) Business Update & Guidance - Management raised full year FY27 revenue growth outlook to exceed 20% (from mid-teens previously). - EBITDA margin improvement for the year expected at the upper end of 75 to 100 bps. - Domestic business grew 12% YoY to ₹1,155Cr with sequential improvement in Zuventus. - International business grew 34.5% YoY to ₹1,665Cr, contributing 59% of total revenue.

Concall Schedule Concall Date: Monday, November 16, 2026 Concall Time: Not specified Event: JM Financial Annual India Conference - India Xchange 2026 in Mumbai.

- Emcure Pharmaceuticals Limited has informed the exchange about the availability of the audio recording for the Q2 FY27 earnings call held on November 03, 2026. - The audio recording can be accessed on the company's official website via the provided link.

- Q2FY27 Revenue from Operations grew 24.3% YoY to ₹2,820.5 Cr, led by 34.5% international and 12% domestic growth. - EBITDA increased 30.9% YoY to ₹574.8 Cr, with EBITDA margins expanding 103 bps to 20.4%. - PAT grew 29.3% YoY to ₹325.1 Cr. - Net debt was ₹1,317.1 Cr as of Sep 30, 2026.

- Emcure Pharmaceuticals Limited submitted financial results for the period ended September 30, 2026. - Detailed financial tables/figures not provided in the announcement.

Concall Schedule Concall Date: November 03, 2026 Concall Time: 4.00 p.m. (IST)

- Board of Directors approved the Scheme of Amalgamation on October 12, 2026. - Involves merging wholly owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited with the holding company Emcure Pharmaceuticals Limited. - Subject to obtaining necessary statutory and regulatory approvals.

- Emcure Pharmaceuticals received orders from the Income-tax Department imposing an aggregate penalty of Rs. 57,73,96,732 for Financial Years 2014-15 to 2020-21. - The company is evaluating legal remedies, including filing an appeal before the Appellate Authority.

- Emcure Pharmaceuticals Limited released its Investor Presentation for September 2026 detailing company overview, business segments, R&D capabilities, and strategic priorities. - Reported FY26 Operating Revenue of USD 1Bn+ (INR 92,035 Mn) with a YoY growth of +16.6%. - PAT for FY26 stood at INR 9,413 Mn representing a 33.1% growth YoY. - Outlined strategic pillars for FY26-FY30 focusing on deepening domestic franchise, scaling international portfolios, and commercializing differentiated R&D platforms.

- At its 45th AGM on September 21, 2026, Emcure Pharmaceuticals Limited approved changes to its Board composition. - Mr. Berjis Desai, Chairman and Non-Executive Non-Independent Director, retired upon the conclusion of the AGM. - Dr. Mukund Gurjar was re-appointed as a Whole-time Director for one year from August 28, 2026. - Mr. Satish Mehta was re-appointed as Managing Director & CEO for five years from April 01, 2027. - Mr. Raghu Kumar was appointed as an Independent Director for three years from August 06, 2026.